DISCLAIMER

Important Information

Melodiol Global Health Limited (ACN 609 406 911) (Company) has lodged a prospectus dated 31 October 2023 (Prospectus) with the Australian Securities and Investment Commission (ASIC):

• a bonus options issue of one (1) option to acquire a fully paid ordinary share (Share) in the capital of the Company (exercisable at $0.015 on or before five years from the date of issue for every twenty (20) Shares held by those eligible shareholders registered at the record date for nil consideration (Bonus Options Offer);
• up to 282,193,935 ME1OD Options to various placement participants and debtors (ME1OD Options Offer);
• up to 334,890,378 ME1O Options to institutional, professional and sophisticated investors that participated in the announcement announced on 8 August 2023 (ME1O Options Offer); and
• up to 10,654,042 ME1OPT57 Options to the various debtors (Unquoted Options Offer);
• up to 10,000 Shares at an issue price of $0.004 per Share to raise up to $40 (before expenses) (Cleansing Offer),

(together, the Offer).

A target market has been specified for investors under the Bonus Options Offer, ME1OD Options Offer and Unquoted Options Offer (Target Market), which is set out in the target market determination available at www.melodiolglobalhealth.com (TMD).

The Prospectus and TMD are an important document which should be read in its entirety. If, after reading the Prospectus you have questions about the Offer, TMD or any other matter, please contact your professional advisers without delay.

Neither ASIC nor ASX Limited, nor any of their respective officers, take any responsibility for the contents of the Prospectus or the merits of the investment to which the Prospectus relates.

The electronic version of the Prospectus accessible through this website and does not constitute an offer of, or an invitation to subscribe for, any securities. You may print out a hard copy of the Prospectus from this website or copy the electronic Prospectus on this website into an electronic file for your personal use only. You must not alter the contents of this electronic file in any way.

Alternatively, you may obtain a hard copy of the Prospectus free of charge by contacting the Company by phone on +61 8 9389 3180 during office hours or by emailing the Company at info@cresopharma.com.

To the extent permitted by law, the Company is not liable for any loss incurred from accessing or downloading the Prospectus from this website, including, but not limited to, data corruption or download.

Entitlement and Acceptance

Anyone who wants to apply for their entitlement under the respective Offers will need to

• Bonus Options Offer: As the Bonus Options Offer is a bonus issue of Bonus Options, eligible shareholders are not required to apply for Bonus Options under the Bonus Options Offer and, accordingly, there is no application form attached to the Prospectus for the Bonus Options Offer.
• ME1OD Options Offer: The ME1OD Options Offer is only being extended to the to various placement participants and debtors (as identified in the Prospectus) (ME1OD Participants). Applications for ME1OD Options under the ME1OD Options Offer must only be made using the application form to be provided by the Company and attached to or accompanying the Prospectus. An application form and instructions on how to apply for ME1OD Options under the ME1OD Options Offer will only be provided to the ME1OD Participants in accordance with the terms of the Prospectus.
• ME1O Options Offer: The ME1O Options Offer is only being extended to the to to institutional, professional and sophisticated investors (as identified in the Prospectus) (ME1O Participants). Applications for ME1O Options under the ME1O Options Offer must only be made using the application form to be provided by the Company and attached to or accompanying the Prospectus. An application form and instructions on how to apply for ME1O Options under the ME1O Options Offer will only be provided to the ME1O Participants in accordance with the terms of the Prospectus.
• Unquoted Options Offer: The Unquoted Options Offer is only being extended to the to various debtors (as identified in the Prospectus) (Participants). Applications for Unquoted Options under the Unquoted Options Offer must only be made using the application form to be provided by the Company and attached to or accompanying the Prospectus. An application form and instructions on how to apply for Unquoted Options under the Unquoted Options Offer will only be provided to the Participants in accordance with the terms of the Prospectus.
• Cleansing Offer: The Cleansing Offer is only being extended to specific parties on invitation by the Company. Applications for Shares under the Cleansing Offer must be made by investors at the direction of the Company and must be made using the application form to be provided by the Company and attached to or accompanying the Prospectus. An application form and instructions on how to apply for Shares under the Cleansing Offer will only be provided to those specific parties invited to participate by the Company.

No Advice

Nothing contained on this website or in the Prospectus constitutes investment, legal, business, tax or other advice. In particular, the information on this website and in the Prospectus does not take into account your investment objectives, financial situation or particular needs. In making an investment decision, you must rely on your own examination of the Company and the securities and terms of the offering, including the merits and risks involved. You should consult your professional adviser for legal, business or tax advice.

Warning

For legal reasons, the electronic version of the Prospectus accessible through this website is available to persons accessing this website from within Australia, New Zealand, Germany, Canada (British Columbia, Nova Scotia, Ontario and Alberta) or United States of America (Colorado) (as instructed by the Company) who are permitted to participate in the Offer as set out in section 2.9 of the Prospectus (Approved Jurisdictions). If you are accessing this website from anywhere outside the Approved Jurisdictions, please do not download the electronic version of the Prospectus.

The Prospectus does not constitute an offer of securities in any jurisdiction where, or to any person to whom, it would not be lawful to issue the Prospectus or make the offer.  It is the responsibility of any applicant outside the Approved Jurisdictions to ensure compliance with all laws of any country relevant to their applications, and any such applicant should consult their professional advisers as to whether any government or other consents are required, or whether any formalities need to be observed to enable them to apply for and be allotted any securities.

It is not practicable for the Company to comply generally with the securities laws of overseas jurisdictions having regard to the number of overseas shareholders, the number and value of securities those shareholders would be offered and the cost of complying with regulatory requirements in each relevant jurisdiction. Accordingly, the offer pursuant to the Prospectus is only being extended and securities will only be issued to shareholders with a registered address in the Approved Jurisdictions and in accordance with the conditions of the Prospectus.

Acknowledgement

By clicking “I Accept” below, you acknowledge and agree that:

• You have read and understood the TMD and that you either fall within the Target Market or, if you do not fall within the Target Market, you are accessing the Prospectus for information purposes only and that you will not make an application under the Prospectus;
• You have read and understood the above terms and conditions to access the electronic version of the Prospectus;
• You are a Approved Jurisdiction resident and you are requesting a copy of the Prospectus from within the Approved Jurisdictions;

OR

• If you are not a resident of an Approved Jurisdictions, you have consulted your professional adviser as to whether any governmental or other consents are required or whether any other formalities need to be considered and followed before accessing the Prospectus; and
• You will not pass onto any other person an application form unless it is attached to or accompanied by the complete and unaltered electronic version of the Prospectus and the TMD.